Adv Ther (2017) 34:2625–2637 DOI 10.1007/s12325-017-0642-4 ORIGINAL RESEARCH Pharmacokinetics and Safety of Amenamevir in Healthy Subjects: Analysis of Four Randomized Phase 1 Studies . . . Tomohiro Kusawake James J. Keirns Donna Kowalski . . . Martin den Adel Dorien Groenendaal-van de Meent Akitsugu Takada Yoshiaki Ohtsu Masataka Katashima Received: September 20, 2017 / Published online: November 13, 2017 The Author(s) 2017. This article is an open access publication Amenamevir was administered orally at various ABSTRACT doses as a single dose (5–2400 mg) or daily (300 or 600 mg/day) for 7 days. Introduction: Amenamevir (ASP2151) is a Results: Following single and multiple oral nonnucleoside antiherpesvirus compound doses, amenamevir demonstrated a less than available for the treatment of varicella–zoster dose proportional increase in the pharmacoki- virus infections. In this article we summarize netic parameters area under the plasma drug the ﬁndings of four phase 1 studies in healthy concentration versus time curve from time zero participants. to inﬁnity (AUC ) and C . After single and inf max Methods: Four randomized phase 1 studies multiple oral 300-mg doses of amenamevir, no investigated the safety and pharmacokinetics of apparent differences in pharmacokinetics were single and multiple doses of amenamevir, observed between
Advances in Therapy – Springer Journals
Published: Nov 13, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera